India-based Lupin has secured U.S. FDA approval for five generic cardiac drugs.
The drugmaker plans to manufacture the drugs from its central India Mihan-SEZ unit, which was previously being used for R&D, and export to the U.S. market. Lupin already makes the branded version of the approved drugs for the domestic market in India.
Lupin's 25 acre plant in Mihan has dedicated 15 acres for tablets and 9 acres for injectables.
Read the Times of India coverage